HIV infection perturbs DNA content of lymphoid cells: Partial correction after 'suppression' of virus replication

AIDS

Volumn 13, Issue 10, 1999, Pages 1177-1185

  Patki, Abhay H ^f   Purvis, Scott F ^f   Valdez, Hernan ^f   Spritzler, John ^a   Connick, Elizabeth ^b   Kuritzkes, Daniel R ^b   Kessler, Harold ^c   Fox, Lawrence ^d   Clair, Marty St ^f   Landay, Alan ^c   Lederman, Michael M ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c RUSH MEDICAL COLLEGE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^f NONE

Author keywords

Antiretroviral therapy; Apoptosis; Cell cycle; DNA synthesis; HIV 1 infection; Peripheral blood lymphocytes; Protease inhibitor

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA; HLA DR ANTIGEN; LAMIVUDINE; PROPIDIUM IODIDE; RITONAVIR; VIRUS RNA; ZIDOVUDINE;

ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA CONTENT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; VIRUS REPLICATION;

ANTI-HIV AGENTS; APOPTOSIS; CELL CYCLE; CROSS-SECTIONAL STUDIES; DNA; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; RITONAVIR; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0008916909     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907090-00005     Document Type: Article

References (25)

1. + levels: results of 6 years of follow up. J Acquir Immune Defic Syndr 1993, 6:904-912.
2. 2. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis 1998, 178:70-79.
3. + T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
4. 4. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry 1992, 13:795-808.
5. 5. McCloskey TW, Oyaizu N, Coronesi M, Pahwa S. Use of a flow cytometric assay to quantitate apoptosis in human lymphocytes. Clin Immunol Immunopathol 1994, 71:14-18.
6. +-T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects. Clin Diagn Lab Immunol 1997, 4:736-741.
7. 7. McCloskey TW, Chavan S, Lakshmi Tamma SM, Pahwa S. Comparison of seven quantitative assays to assess lymphocyte cell death during HIV infection: Measurement of induced apoptosis in anti-Fas-treated Jurkat cells and spontaneous apoptosis in peripheral blood mononuclear cells from children infected with HIV. AIDS Res Hum Retroviruses 1998, 14:1413-1422.
8. 8. AIDS clinical trials group immunology laboratory committee consensus methodologies. Bethesda, MD: NIH, 1997; http://aartg.s-3.com
9. 9. Van GB, Beuningen VR, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electro-chemiluminescent (ECL) labelled probes. J Virol Methods 1996, 49:157-168.
10. 10. Adachi Y, Oyaizu N, Than S, McCloskey TW, Pahwa S. IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection. Correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 1996, 157:4184-4195.
11. 11. Pierdominici M, Mollicone B, Ricci G, et al. Apoptosis in asymptomatic HIV-1 seropositives immunized with HIV-1 env glycoprotein (gp160): effects of administration of zidovudine in vivo and interleukin-2 in vitro. Vaccine 1998, 16:715-721.
12. 12. Klein SA, Dobmeyer JM, Dobmeyer TS, et al. TNF-alpha mediated apoptosis of CD4 positive T-lymphocytes. A model of T-cell depletion in HIV infected individuals. Eur J Med Res 1996, 1:249-258.
13. 13. Chehimi J, Marshall JD, Salvucci O, et al. IL-15 enhances immune functions during HIV infection. J Immunol 1997, 158:5978-5987.
14. 14. Estaquier J, Idziorek T, Zou W, et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995, 182:1759-1767.
15. 15. Poon B, Grovit-Ferbas K, Stewart SA, Chen ISY. Cell cycle arrest by Vpr in HIV-1 virions and insensitivity to antiretroviral agents. Science 1998, 281:266-269.
16. 16. Stewart SA, Poon B, Jowett JB, Chen IS. Human immunodeficiency virus type 1 Vpr induces apoptosis following cell cycle arrest. J Virol 1997, 71:5579-5592.
17. + T-cell production may go unnoticed [letter]. AIDS 1999, 13:290-291.
18. + T-cell pool during HIV-1 infection and triple combination therapy. AIDS 1998, 12:879-884.
19. 19. Sachsenberg N, Perelson AS, Yerly S, et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998, 187:1295-1303.
20. 20. Orendi JM, Bloem AC, Borleffs JC, et al. Activation and cell cycle antigens in CD4+ and CD8+ T cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998, 178:1279-1287.
21. + T-cell renewal in early HIV-1 infection: Effect of highly active antiretroviral therapy. Nature Med 1998, 4:794-801.
22. 22. Connick E, Lederman M, Kotzin B, et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. 5th Conference on Retroviruses and Opportunistic Infections. Place, February 1998 [abstract LB14].
23. 23. Giorgi JV, Majchrowics, Johnson TD, Hultin P, Matud J, Detels R. Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV-1 infection. AIDS 1998, 12:1833-1844.
24. 24. Aukrust P, Muller F, Lien E, et al. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999, 179:74-82.
25. 25. Badley AD, Dockrell DH, Algeciras A, et al.: In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998, 102:79-87.